NDC product
Harvoni
NDC 61958-1804 · Gilead Sciences, Inc
Key facts
| Product NDC | 61958-1804 |
|---|---|
| Proprietary name | Harvoni |
| Nonproprietary name | ledipasvir and sofosbuvir |
| Substances | LEDIPASVIR, SOFOSBUVIR |
| Dosage form | PELLET |
| Route | ORAL |
| Labeler | Gilead Sciences, Inc |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA212477 |
| Pharmacologic classes | Breast Cancer Resistance Protein Inhibitors [MoA], Hepatitis C Virus NS5A Inhibitor [EPC], Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC], P-Glycoprotein Inhibitors [MoA], RNA Replicase Inhibitors [MoA] |
| Marketing start | Aug 28, 2019 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: